Literature DB >> 15029257

A WT1 expressing metastatic human Kaposi sarcoma xenograft model.

Erzsébet Rásó1, Lívia Mészáros, Adriana Albini, József Tímár.   

Abstract

We have established a non-metastatic and a metastatic human Kaposi sarcoma (KS) xenograft model in SCID mice by injecting KS-Imm cells subcutaneously and intrasplenically, respectively. KS-Imm cells expressed endothelial markers, CD34 and vWF in vivo. Furthermore, we have shown that these cells express all the splice variants of the WT1 gene and WT1wt protein in vitro and in vivo detected by nested PCR and immunohistochemistry. WT1 expression in the peripheral blood was only detectable in case of metastatic KS model suggesting it as a molecular marker of progression.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15029257     DOI： 10.1007/BF02893404

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  18 in total

1.  Putting the neo into neoangiogenesis.

Authors:  Malcolm A S Moore
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes.

Authors:  Silvia Montaner; Akrit Sodhi; Alfredo Molinolo; Thomas H Bugge; Earl T Sawai; Yunsheng He; Yi Li; Patricio E Ray; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

3.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.

Authors:  U Maurer; J Brieger; E Weidmann; P S Mitrou; D Hoelzer; L Bergmann
Journal:  Exp Hematol       Date:  1997-08       Impact factor: 3.084

4.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.

Authors:  L Jussila; R Valtola; T A Partanen; P Salven; P Heikkilä; M T Matikainen; R Renkonen; A Kaipainen; M Detmar; E Tschachler; R Alitalo; K Alitalo
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

5.  Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.

Authors:  E Magyarosy; N Varga; J Timár; E Rásó
Journal:  Pediatr Hematol Oncol       Date:  2003 Jan-Feb       Impact factor: 1.969

6.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

Authors:  U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

7.  The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.

Authors:  L W Ellisen; N Carlesso; T Cheng; D T Scadden; D A Haber
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

8.  Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas.

Authors:  Harriette J Kahn; Denis Bailey; Alexander Marks
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

9.  Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas.

Authors:  A L Folpe; T Veikkola; R Valtola; S W Weiss
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

10.  Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells.

Authors:  Ashlee V Moses; Michael A Jarvis; Camilo Raggo; Yolanda C Bell; Rebecca Ruhl; B G Mattias Luukkonen; Diana J Griffith; Cecily L Wait; Brian J Druker; Michael C Heinrich; Jay A Nelson; Klaus Früh
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103
View more
  1 in total

1.  Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest.

Authors:  Bíborka Bereczky; Réka Gilly; Erzsébet Rásó; Agnes Vágó; József Tímár; József Tóvári
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.